Impax Laboratories

Prior to its acquisition by Amneal Pharmaceuticals in May 2018, Impax Laboratories was a leading U.S. specialty pharma company with a dual platform strategy—developing both generics and proprietary branded drugs. Its pipeline included complex generics and innovative controlled-release formulations. The company had commercialized dozens of products across multiple therapeutic areas, with particular strength in CNS disorders such as Parkinson’s disease[4][6].

Pipeline breadth: At the time of its last independent reporting period before the merger, Impax had over forty-seven commercialized generic products plus several branded drugs; it also had numerous additional programs in development or pending approval[6].